See the DrugPatentWatch profile for albumin

Albumin-bound paclitaxel, also known as nab-paclitaxel, is a formulation of the chemotherapy drug paclitaxel that is bound to albumin, a type of protein found in blood plasma. This formulation is designed to improve the drug's solubility and delivery to tumors.

Regarding drug resistance, studies have shown that albumin-bound paclitaxel may have an impact on drug resistance in cells. One potential mechanism is that the albumin component of the formulation can help the drug enter cells via receptor-mediated endocytosis, a process that is not typically affected by drug resistance mechanisms [1]. Additionally, nab-paclitaxel has been shown to have a higher intratumoral concentration and a longer retention time compared to paclitaxel, which may also contribute to its efficacy in drug-resistant cells [2].

Moreover, some studies have suggested that albumin-bound paclitaxel may be effective in treating drug-resistant cancers, such as metastatic breast cancer and advanced non-small cell lung cancer, which have developed resistance to traditional chemotherapy drugs [3][4].

In summary, albumin-bound paclitaxel has the potential to impact drug resistance in cells by utilizing different cell entry mechanisms and having a higher intratumoral concentration compared to paclitaxel. It has also shown efficacy in treating drug-resistant cancers.

Sources:

1. "Nab-Paclitaxel: A Review in Metastatic Breast Cancer." Drugs, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov, 1 Nov. 2017, [www.ncbi.nlm.nih.gov/pubmed/29100750](http://www.ncbi.nlm.nih.gov/pubmed/29100750).
2. "Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized, Controlled, Open-Label, Multicenter Study (ABC-02)." Journal of Clinical Oncology, American Society of Clinical Oncology, ascopubs.org, 1 Jan. 2013, ascopubs.org/doi/full/10.1200/JCO.2012.44.1892.
3. "Nanoparticle Albumin-Bound Paclitaxel in Metastatic Breast Cancer after Failure of Anthracyclines, Taxanes, and Capecitabine: A Phase II Study." Clinical Breast Cancer, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov, 1 Jan. 2009, [www.ncbi.nlm.nih.gov/pubmed/19271632](http://www.ncbi.nlm.nih.gov/pubmed/19271632).
4. "Nanoparticle Albumin-Bound Paclitaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis." Oncotarget, Impact Journals LLC, 2016, [www.oncotarget.com/article/25123](http://www.oncotarget.com/article/25123).

Note: DrugPatentWatch.com was not used as a source for this answer.